An Update to Our Healthcare Partners 

June 17, 2020

Dear Valued Healthcare Partners,

For many of you, COVID-19 has been one of the most trying times of your career, if not your personal lives as well. And now, the reminders of persistent racism in our nation and the resulting violence in our communities have resulted in a new wave of anxiety and uncertainty for all of us. We hope you, your families and your practices are doing well throughout these events. 

Please know that Nevro stands firmly against unfair discrimination on any basis, including race. We are committed to a diverse workforce and to equal treatment and respect for all our team members. In turn, our team is committed to you and your patients. We know that is why we’re here, and that is our mission. 

Despite the turmoil around us, that commitment has not wavered. In this letter I have further updates on some new patient insights and new product approvals.

Insights into Pain Patient Needs

In an effort to better understand how chronic pain patients are feeling about exploring treatment options during COVID-19, we fielded a survey in mid-May to 175 prospective patients who previously completed the SCS questionnaire on our patient site
The survey provides unique insights for you, so we packaged the results in a seven page report that summarizes the findings. This report is available online here and below are a few highlights.

  • The patients surveyed were well qualified for SCS
    • 93% of respondents have experienced chronic pain for over twelve months and 68% indicated a pain score of 7 or higher.
  • Most patients felt comfortable about seeking near-term care:
    • 73% of participants saying they are likely or extremely likely to see a pain specialist over the next three months.
  • Some patients cited a few specific concerns about next steps in their care:
    • 26% of participants cited that their primary reason for postponing treatment is due to their fears of contracting COVID-19 in a healthcare setting
    • An additional 22% cited concerns with high out-of-pocket costs. 

The report further outlines steps providers can take to alleviate patient safety concerns and also reviews patient thoughts on telemedicine. We hope this information is useful to you.

Global Patient Support

Our dedication to patient support and long-term outcomes is fundamental to our company and is something we continue to invest in and report back to you. I’m pleased to provide some updates on our further progress made just since the start of the pandemic:

  • Globally, our organization has now conducted approximately 100,000 phone calls with patients
  • During these calls, over 11,000 implanted patients have had their therapy optimized.
  • 43% of these patients have seen an improvement in their pain relief.

These results are thanks to our unique ability to provide ongoing patient support through our patient care infrastructure of phone-based therapy support specialists, field-based teams, and the NevroCloud patient management platform.

Product Approvals Continue

Our commitment to Clinical Research, R&D, and new product development has remained steady throughout the pandemic. In my last communication I shared the Omnia system had been CE marked and was on the verge of launching in Europe. Cases with Omnia have now been performed in countries across Europe and our physician customers are expressing excitement about gaining access to the versatility of the platform. 

Additionally, I am pleased to share that we have received TGA approval for Australia and have just learned that Omnia will be added to the Prostheses List on July 1st. Our local team is fully trained and ready to launch Omnia on this date. With this latest milestone Omnia has now been approved and will soon be available in all our major markets globally.

Loss of a Legend

Our community was recently met by a great loss as we learned of the passing of Lisa Stearns, MD, a legend in the Pain community who served as a role model to countless physicians around the globe. She was a caring and compassionate provider for those in pain and was a pioneer for helping patients suffering from pain associated with cancer. She will be remembered not just for her significant professional accomplishments, but also because she embodied the best of humanity.

Thank you for your continued partnership and we wish you and your loved ones good health.


D. Keith Grossman

Chairman, CEO and President, Nevro Corporation